We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
Cap. Flow
-$726M
Cap. Flow %
-15.73%
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$97.5M
2
SGRY icon
Surgery Partners
SGRY
+$75.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$60M
4
PRTA icon
Prothena Corp
PRTA
+$57.7M
5
ARGX icon
argenx
ARGX
+$49.8M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$280M
2
BIIB icon
Biogen
BIIB
+$160M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$120M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$104M
5
HUM icon
Humana
HUM
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
2 Miscellaneous 7.3%
3 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$337M 7.3%
+4,062,000
New +$329M
ARGX icon
2
argenx
ARGX
$64B
$237M 5.13%
625,000
+133,200
+27% +$49.8M
UTHR icon
3
United Therapeutics
UTHR
$22.1B
$218M 4.73%
785,500
-184,700
-19% -$46.6M
NBIX icon
4
Neurocrine Biosciences
NBIX
$15.7B
$213M 4.61%
1,780,000
-75,700
-4% -$8.87M
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$210M 4.54%
3,825,000
+703,000
+23% +$30.1M
PRTA icon
6
Prothena Corp
PRTA
$479M
$178M 3.85%
2,953,000
+986,000
+50% +$57.7M
ARVN icon
7
Arvinas
ARVN
$600M
$169M 3.67%
4,950,000
+606,500
+14% +$25.5M
BSX icon
8
Boston Scientific
BSX
$67.9B
$151M 3.26%
3,256,700
+718,100
+28% +$31.1M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.74B
$149M 3.23%
5,861,000
+274,100
+5% +$6.39M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.52B
$139M 3%
2,990,000
+938,400
+46% +$36.9M
SRPT icon
11
Sarepta Therapeutics
SRPT
$2.2B
$137M 2.96%
1,055,000
+106,800
+11% +$12.4M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.3B
$125M 2.7%
+430,000
New +$42.1M
UHS icon
13
Universal Health Services
UHS
$10.1B
$116M 2.52%
+825,600
New +$97.5M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.9B
$116M 2.51%
727,541
+409,241
+129% +$60M
ZNTL icon
15
Zentalis Pharmaceuticals
ZNTL
$360M
$104M 2.25%
5,150,000
+926,900
+22% +$19.9M
ACHC icon
16
Acadia Healthcare
ACHC
$2.66B
$95.9M 2.08%
1,165,000
-224,200
-16% -$18.5M
SGRY icon
17
Surgery Partners
SGRY
$1.79B
$86.7M 1.88%
3,112,000
+2,844,400
+1,063% +$75.3M
DXCM icon
18
DexCom
DXCM
$34.3B
$85.7M 1.86%
756,800
+289,200
+62% +$31.8M
AZN icon
19
AstraZeneca
AZN
$252B
$81.4M 1.76%
600,000
+318,400
+113% +$39.9M
LLY icon
20
Eli Lilly
LLY
$1.05T
$79.4M 1.72%
217,000
-790,000
-78% -$280M
PCVX icon
21
Vaxcyte
PCVX
$8.9B
$77.5M 1.68%
1,615,400
+986,700
+157% +$38.7M
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$72.7M 1.57%
3,275,000
+675,000
+26% +$10.1M
NTRA icon
23
Natera
NTRA
$47B
$72.3M 1.57%
1,798,900
+63,900
+4% +$2.63M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.87B
$69.5M 1.51%
3,824,800
+109,400
+3% +$1.84M
IMCR icon
25
Immunocore
IMCR
$1.89B
$65.9M 1.43%
1,154,000
-925,100
-44% -$52.1M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q4 2022 Portfolio in Review

As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management withdrew a net $726M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.

  • Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
  • Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
  • Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
  • Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
  • Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
  • Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.